Valuation: OLIPASS Corporation

Market Cap 26.53B 17.84M 15.59M 14.39M 13.26M 25M 1.72B 25.55M 172M 67.64M 841M 67M 65.53M 2.9B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 13.68M 11.95M 11.03M 10.17M 19.16M 1.32B 19.58M 132M 51.85M 645M 51.36M 50.23M 2.22B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
158,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-90.86% 9.09M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-8.41%+3.57%+425.83% 23.29B
-0.09%-1.61%-18.68%-15.48% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-2.07%+24.79%+188.40% 14B
Average -3.87%-5.72%+39.73%+163.22% 24.05B
Weighted average by Cap. -2.90%-2.20%+43.58%+157.02%

Financials

2021 2022
Net sales 852M 573K 501K 462K 426K 803K 55.16M 820K 5.52M 2.17M 27.02M 2.15M 2.1M 93M 2.3B 1.54M 1.35M 1.25M 1.15M 2.16M 149M 2.21M 14.88M 5.85M 72.83M 5.8M 5.67M 251M
Net income -25.13B -16.9M -14.77M -13.63M -12.56M -23.68M -1.63B -24.21M -163M -64.08M -797M -63.48M -62.09M -2.74B -24.17B -16.25M -14.2M -13.11M -12.08M -22.77M -1.57B -23.28M -157M -61.62M -767M -61.04M -59.7M -2.64B
Net Debt -18.29B -12.3M -10.75M -9.92M -9.14M -17.23M -1.18B -17.62M -119M -46.63M -580M -46.19M -45.18M -2B -6.2B -4.17M -3.64M -3.36M -3.1M -5.84M -401M -5.97M -40.16M -15.79M -196M -15.65M -15.3M -676M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
78
  1. Stock Market
  2. Stocks
  3. A244460 Stock